Helsinki-based Gosta Labs has raised €7.5m in seed funding to scale its oncology AI operating system for cancer care teams.
The company, founded by former Kaiku Health founders Lauri Sippola and Henri Viertolahti, develops technology that automates clinical documentation and transforms patient visits into structured data in real time. Kaiku Health was acquired by Elekta in 2020.
The system summarises patient journeys, automates note-taking, and links treatment decisions to international guidelines. It aims to reduce the hours clinicians spend on administrative tasks within fragmented systems while managing increasingly complex cancer care.
By 2050, more than 35 million new cancer cases are expected to be diagnosed across over 100 different types, according to IARC data. The growing number of personalised treatment options adds to the complexity facing multidisciplinary teams making high-stakes decisions.
First real-world results presented at the ESMO 2025 Congress showed oncologists completed follow-up visit documentation in a median time of under two minutes. The system automatically classifies Performance Status (a measure of how well a patient can perform daily activities) and CTCAE toxicity grades (standardised measures of treatment side effects).
“This technology is already reshaping our clinical workflows. The ability to produce structured, accurate notes instantly and classify key clinical parameters automatically frees oncologists to spend their time where it matters most — with their patients.” Said Dr Razvan Popescu, medical director at Tumor Center Aargau and lead investigator in the study.
“In practice, this has already cut documentation time by over two-thirds for each patient visit at our cancer centre.”
The AI system is currently operational with healthcare providers in Finland, Switzerland, the Baltics and Australia.
The seed round was led by Voima Ventures, with participation from COR Group, the Aho family, Reaktor and angel investors. This follows a €1.7m pre-seed round in 2024, bringing total funding to nearly €10m.
“Gosta Labs’ key team members combine proven startup execution, deep domain expertise and top notch AI capabilities. They’ve done it before and know what good looks like, which is an essential for any startup team.” said Jussi Sainiemi, partner at Voima Ventures.
“There’s a lot of hype around AI but Gosta delivers the value it promises and customers love the product.”
The company’s leadership team includes chief medical officer Dr Lionel Hadjadjeba and chief operating officer Reetta Arokoski, both with decades of experience in scaling cancer-care technologies internationally.
“We started Gosta Labs to bring AI to support extremely complex medical specialities like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day.” said Lauri Sippola, chief executive officer and co-founder.
This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration.
Founded in 2023, Gosta Labs develops what it describes as an AI operating system for complex medical specialities, with an initial focus on oncology.
